0.5 ml dose of PCV20

BIOLOGICAL2 trials

Sponsors

Vaxcyte, Inc.

Conditions

Pneumococcal Vaccines

Phase 2

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

CompletedNCT05844423

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2023-03-29End: 2025-08-25Updated: 2025-09-11

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Active, not recruitingNCT06720038

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2024-11-25End: 2027-12-01Updated: 2026-05-15